In 2016, the U.S. Preventive Services Task Force (USPSTF) gave colorectal cancer (CRC) screening an “A” grade, stating high certainty of substantial net benefit in average-risk, asymptomatic adults aged 50 to 75 years (1). The recommendation detailed the screening strategies supported by scientific evidence, as well as the types of evidence for and advantages and limitations of each practice. With no empirical data to demonstrate that any strategy had greater net benefit than another, the USPSTF declined to endorse a single strategy, highlighting instead the need to increase CRC screening generally because one third of eligible U.S. adults are not current with any effective practice for CRC screening.